Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Types

    ... divides MDS in to five subtypes based on percentage of blasts in the bone marrow and the peripheral blood. It is now used ... FAB-type % blasts in blood % blasts in bone marrow ...

    Topic section last updated 11/14/2016 - 1:11pm.

  2. Allogeneic Hematopoietic Stem Cell Transplantation is Underutilized in Older Patients with Myelodysplastic Syndromes

    ... (p=0.008), intermediate-1/low risk MDS (p<0.001), <5% blasts at diagnosis (overall p<0.001), having medicare/medicaid health ... between 2008-2011 (p<0.001), age ≥65 (p=0.001) and <5% blasts at diagnosis (overall p=0.031) were associated with a lower likelihood ...

    Research Article last updated 04/14/2017 - 9:28am.

  3. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.

    ... of dysplasia (such as ring sideroblasts or excess of blasts ). Therefore, there is clearly need to refine the accuracy to detect ...

    Research Article last updated 03/22/2017 - 9:18am.

  4. Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy

    ... analysis, adverse cytogenetics , excess of blasts at the initiation of LEN, and the type of failure (classified as ...

    Research Article last updated 02/21/2017 - 9:43am.

  5. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    ... 53 (46%) had bone marrow blast clearance (<5% blasts ). Response rates were higher among patients with an unfavorable-risk ...

    Research Article last updated 01/26/2017 - 10:07am.

  6. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

    ... in myelodysplastic syndromes (MDS), clonal blasts gain a more aggressive nature, whereas nonclonal immune cells ... and tumor necrosis factor-alpha (TNFalpha) on MDS blasts. This induction was associated with the activation of nuclear ... inhibitor, pyrrolidine dithiocarbamate (PDTC). B7-H1(+) MDS blasts had greater intrinsic proliferative capacity than B7-H1(-) MDS blasts ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group

    ... with MDS and acute myeloid leukaemia (AML) with 20-29% blasts were enrolled. Data collection was conducted for strictly predefined ...

    Research Article last updated 11/02/2016 - 10:17am.

  8. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?

    ... Although patients who undergo alloSCT with excess blasts have poorer outcomes than those transplanted with fewer blasts, the effect of clone size in patients with MDS without increased ...

    Research Article last updated 04/29/2016 - 10:22am.

  9. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes

    ... to patients with refractory anaemia with excess blasts (RAEB). In 2025 HMA-treated patients, median survival was 15 months ...

    Research Article last updated 10/06/2016 - 11:34am.

  10. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... in patients with myelodysplastic syndromes with excess blasts after failure of azacitidine or decitabine ... with diagnosis of refractory anaemia with excess blasts (RAEB)-1, RAEB-2, RAEB-t, or chronic myelomonocytic leukaemia based on ...

    Research Article last updated 06/07/2016 - 11:10am.